Several other research firms have also recently commented on TH. Mackie lowered their price target on shares of Theratechnologies from C$5.30 to C$4.40 in a report on Wednesday, July 6th. Canaccord Genuity decreased their price objective on shares of Theratechnologies from C$4.25 to C$3.75 in a report on Thursday, July 7th.
Shares of Theratechnologies (TSE:TH) traded up 1.74% on Thursday, reaching $2.92. The company had a trading volume of 11,508 shares. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.42. The stock has a market capitalization of $192.52 million and a PE ratio of 265.45. Theratechnologies has a 52-week low of $1.26 and a 52-week high of $3.74.
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.